Found 6 results
Author Title Type [ Year(Asc)]
Filters: Author is Nussenblatt, Robert B  [Clear All Filters]
2009
N. H Sen, Levy-Clarke, G., Faia, L. J., Li, Z., Yeh, S., Barron, K. S., Ryan, J. G., Hammel, K., and Nussenblatt, R. B., “High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.”, Am J Ophthalmol, vol. 148, no. 5, pp. 696-703.e1, 2009.
N. H Sen, Sangave, A., Hammel, K., Levy-Clarke, G., and Nussenblatt, R. B., “Infliximab for the treatment of active scleritis.”, Can J Ophthalmol, vol. 44, no. 3, pp. e9-e12, 2009.
2007
R. R. Buggage, Levy-Clarke, G., Sen, H. N., Ursea, R., Srivastava, S. K., Suhler, E. B., Altemare, C., Velez, G., Ragheb, J., Chan, C. - C., Nussenblatt, R. B., Bamji, A. T., Sran, P., Waldmann, T., and Thompson, D. J. S., “A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.”, Ocul Immunol Inflamm, vol. 15, no. 2, pp. 63-70, 2007.
2006
R. B. Nussenblatt, Kim, J., Thompson, D. J. S., Davis, M. D., Chew, E., Ferris, F. L., and Buggage, R., “Vitamin E in the treatment of uveitis-associated macular edema.”, Am J Ophthalmol, vol. 141, no. 1, pp. 193-4, 2006.
2005
R. B. Nussenblatt, Peterson, J. S., C Foster, S., Rao, N. A., See, R. F., Letko, E., and Buggage, R. R., “Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.”, Ophthalmology, vol. 112, no. 5, pp. 764-70, 2005.
2003
R. B. Nussenblatt, Thompson, D. J. S., Li, Z., Chan, C. Chao, Peterson, J. S., Robinson, R. R., Shames, R. S., Nagarajan, S., Tang, M. Tao, Mailman, M., Velez, G., Roy, C., Levy-Clarke, G. A., Suhler, E. B., Djalilian, A., Sen, H. Nida, Al-Khatib, S., Ursea, R., Srivastava, S., Bamji, A., Mellow, S., Sran, P., Waldmann, T. A., and Buggage, R. R., “Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.”, J Autoimmun, vol. 21, no. 3, pp. 283-93, 2003.